Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $60.1MThe company’s own SEC segment disclosure.
- US$36.9M61%
- Non Us$23.2M39%
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $71M in Q2 2026 (quarter ended June 30, 2026), up 47% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $49M. For the full year FY2025, revenue was $190M (+46% year on year) and net income −$197M. Its largest region in 2026-Q1 was US at $37M, 61% of the disclosed total, just ahead of Non Us at 39%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.